Skip to main content
. 2021 Aug 28;16:166. doi: 10.1186/s13014-021-01879-2

Table 2.

Neuro-ophthalmologic findings by treatment group

Neuro-ophthalmologic finding Treatment group p-value
cFSRT hSRT
n Median (IQR) or n (%) n Median (IQR) or n (%)
ΔLogMAR, worse eye 35 0.00 (− 0.05, 0.10) 13 0.05 (0.00, 0.50) 0.092
Clinically relevant VA deterioration (ΔLogMAR ≥ 0.2), worse eye 35 6 (17%) 13 6 (46%) 0.061
ΔMD, worse eye (dB) 16 2.4 (− 0.2, 4.5) 4 0.1 (− 4.2, 6.6) 0.682
ΔLogMAR, better eye 33 0.00 (− 0.02, 0.03) 12 0.00 (0.00, 0.07) 0.869
Clinically relevant VA deterioration (ΔLogMAR ≥ 0.2), better eye 33 1 (3%) 12 1 (8%) 0.467
ΔMD, better eye (dB) 21 0.6 (− 1.2, 1.7) 5 1.5 (− 4.7, 2.4)  > 0.999
Optic disc abnormality (worse eye)
 Pretreatment 33

Atrophy: 18 (55%)

Edema: 7 (21%)

Other: 0 (0%)

11

Atrophy: 3 (27%)

Edema: 0 (0%)

Other: 0 (0%)

0.016
 Final evaluation 31

Atrophy: 20 (65%)

Edema: 0 (0%)

Other: 0 (0%)

11

Atrophy: 3 (27%)

Edema: 0 (0%)

Other: 0 (0%)

0.043
Any optic disc abnormality (atrophy, edema, or other abnormality)
 Pretreatment 33 25 (76%) 11 3 (27%) 0.009
CN V1 involvement
 Pretreatment 28 1 (4%) 9 3 (33%) 0.038
 Final evaluation 29 5 (17%) 12 2 (17%)  > 0.999
Chronic ocular disease 33 3 (9%) 12 0 (0%) 0.553
Radiation-induced Optic Neuropathy (RION)
 During 1st year after treatment 24 1 (4%) 10 0 (0%)  > 0.999
 Final evaluation 31 1 (3%) 11 0 (0%)  > 0.999
Radiation retinopathy
 During 1st year after treatment 25 1 (4%) 10 0 (0%)  > 0.999
 Final evaluation 31 4 (13%) 11 1 (9%)  > 0.999

Values in italics denote findings of noteworthy differences between radiotherapy regiments

AVPM anterior visual pathway meningioma; hSRT, hypofractionated stereotactic radiotherapy; cFSRT conventionally fractionated stereotactic radiotherapy; IQR interquartile range; LogMAR logarithm of minimum angle of resolution; MD mean deviation; ∆LogMAR final LogMAR minus pretreatment LogMAR; ΔMD = final MD minus pretreatment MD; VA visual acuity; CN cranial nerve